Citi says Novartis selloff on neuromuscular trial failure looks overdone
Citi analysts said Novartis’s stock selloff following a neuromuscular drug clinical-trial failure looks overdone. They added the company reiterated its 2025-2030 outlook and noted upcoming study results could be more positive.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.